LOS ANGELES, California, April 25, 2007 – VCA Antech, Inc. (NASDAQ Global Select Market: WOOF), a leading animal healthcare company in the United States, today reported financial results for the quarter ended March 31, 2007, as follows: revenue increased 13.2% to a first quarter record of $265.1 million; gross profit increased 19.5% to $75.9 million; operating income increased 21.4% to $54.3 million; net income was $28.3 million; and diluted earnings per common share was $0.33.
The first quarter of 2006 included a tax benefit of $6.8 million, or $0.08 per diluted common share, due to a favorable outcome of an income tax audit that resulted in a change to our estimated tax liabilities. Excluding this item from 2006, adjusted net income increased 23.9% to $28.3 million and adjusted diluted earnings per common share increased 22.2% to $0.33.
Bob Antin, Chairman and CEO, stated, "We experienced a very strong quarter. Our consolidated revenue increased 13.2% to $265.1 million. Our consolidated gross profit increased 19.5% and our consolidated operating income increased 21.4%. Our consolidated gross margin increased to 28.6% compared to 27.1% in the comparable prior year quarter. In addition, our consolidated operating margin increased to 20.5% compared to 19.1% in the comparable prior year quarter.
"Our laboratory revenue increased 19.6% to $73.6 million. Our laboratory gross profit increased 26.1% and our laboratory gross margin increased to 48.9% compared to 46.4% in the comparable prior year quarter. Our laboratory operating income increased 27.0% and our laboratory operating margin increased to 42.2% compared to 39.7% in the comparable prior year quarter. Laboratory internal revenue growth was 17.4% for the first quarter of 2007.
"Our animal hospital revenue increased 9.8% to $187.2 million. Our animal hospital same-store revenue growth was 5.5% for the first quarter of 2007 and our animal hospital same-store gross margin increased to 19.2% compared to 19.1% in the comparable prior year quarter. Due to our recent animal hospital acquisitions, our consolidated animal hospital gross margin declined to 19.0% compared to 19.1% in the comparable prior year quarter. In addition, our consolidated animal hospital operating margin declined to 16.0% compared to 16.4% in the comparable prior year quarter.
"Our medical technology revenue increased 39.8% to $11.2 million and our medical technology gross profit increased 72.3% to $4.3 million, while our medical technology gross margin increased to 38.6% compared to 31.3% in the comparable prior year quarter. Our medical technology operating income was $1.4 million compared to an operating loss of $149,000 reported in the first quarter of 2006."
Non-GAAP Financial Measures
We believe investors' understanding of our total performance is enhanced by disclosing adjusted net income and adjusted diluted earnings per common share. We define adjusted net income and adjusted diluted earnings per common share as the reported items, adjusted to exclude certain significant items. Adjusted diluted earnings per common share is adjusted net income divided by diluted common shares outstanding.
Management uses adjusted net income and adjusted diluted earnings per common share because they exclude the effect of significant items that we believe are not representative of our core operations for the periods presented. As a result, these non-GAAP financial measures help to provide meaningful comparisons of our overall performance from one reporting period to another and meaningful assessments of our future performance and related trends. For the quarter ended March 31, 2006, the only item excluded in computing adjusted net income and adjusted diluted earnings per common share was a $6.8 million tax benefit. For the quarter ended March 31, 2007, there were no adjustments.
There is a material limitation associated with the use of these non-GAAP financial measures: our computation of adjusted net income for the quarter ended March 31, 2006, excludes the impact of the $6.8 million tax benefit and as a result, our computation of adjusted diluted earnings per common share does not depict diluted earnings per common share in accordance with GAAP.
To compensate for the limitations in the non-GAAP financial measures discussed above, our disclosures provide a complete understanding of all adjustments found in non-GAAP financial measures, and we reconcile the non-GAAP financial measures to the GAAP financial measures in the attached financial schedules titled "Supplemental Operating Data."
We will discuss our company's first quarter 2007 financial results during a conference call today, April 25, 2007 at 4:30 p.m. Eastern Time. You can access a live broadcast of the call by visiting our website at http://investor.vcaantech.com. You can also access the call via telephone by dialing (800) 475-3716. Interested parties should call at least 10 minutes prior to the start of the call to register.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Among the important factors that could cause actual results to differ are: a material adverse change in our financial condition or operations; the rate of our laboratory internal revenue growth and animal hospital same-store revenue growth; the level of direct costs and our ability to maintain revenue at a level necessary to maintain expected operating margins; the level of selling, general and administrative costs; the effects of our recent acquisitions and our ability to effectively manage our growth and achieve operating synergies; a continued decline in demand for some of our products and services; any disruption in our information technology systems or transportation networks; the effects of competition; any impairment in the carrying value of our goodwill; changes in prevailing interest rates; our ability to service our debt; and general economic conditions. These and other risk factors are discussed in our report on Form 10-K for the year ended December 31, 2006, and the reader is directed to these statements for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements.
We own, operate and manage the largest networks of freestanding veterinary hospitals and veterinary-exclusive clinical laboratories in the country, and we supply diagnostic imaging equipment to the veterinary industry.
Tomas Fuller, Chief Financial Officer